Jun 16, 2026 08:00AM
Jun 16, 2026 08:00AM
May 25, 2026 03:33AM
May 15, 2026 02:55AM
May 8, 2026 09:00AM
May 8, 2026 02:48AM
May 8, 2026 02:48AM FDA extends Leqembi Iqlik review period to August 24
May 8, 2026 02:47AM
Apr 21, 2026 07:01AM
Apr 21, 2026 07:00AM
Mar 24, 2026 09:00AM
Mar 23, 2026 03:50AM
Feb 6, 2026 06:17AM
Jan 21, 2026 10:30PM BioAge prices $115 million upsized public offering at $19.50 per share
Jan 21, 2026 10:30PM
Jan 20, 2026 04:01PM
Jan 20, 2026 04:01PM
Jan 20, 2026 09:01AM
Jan 20, 2026 09:00AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated
Dec 8, 2025 06:42PM
Dec 4, 2025 09:01AM
Dec 4, 2025 09:00AM
Dec 4, 2025 02:13AM
Nov 18, 2025 07:02PM
Nov 13, 2025 06:50PM
Nov 6, 2025 04:45PM BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
Oct 26, 2025 10:56PM
Sep 2, 2025 11:01PM
Aug 25, 2025 03:26AM
Aug 15, 2025 09:00AM
Aug 15, 2025 09:00AM
Aug 6, 2025 04:30PM
Jul 30, 2025 10:54PM BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
Jun 21, 2025 06:00PM
Jun 17, 2025 09:08AM
Jun 17, 2025 09:00AM
Jun 3, 2025 09:00AM
May 29, 2025 09:00AM
May 29, 2025 09:00AM
May 15, 2025 04:56AM Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
May 8, 2025 07:49AM
May 6, 2025 04:30PM
Apr 24, 2025 08:28AM
Apr 22, 2025 08:13AM
Apr 1, 2025 06:14AM
Mar 25, 2025 03:08AM
Mar 17, 2025 02:34PM BioAge Labs (BIOA) recieves FDA orphan drug destination for exidavnemab
Mar 17, 2025 01:49PM

323,570 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All